Table 1.

Overall survival for PM cohort of 306 patients with AML by LSC17 score, continuous or discretized, as measured by research and clinical assays

Overall survival	Continuous scores univariate analysis (n = 306)*		Discretized scores univariate analysis (n = 306)*
Covariate	Hazard ratio (95% CI)†	P ‡	Hazard ratio (95% CI)†	P ‡
High score (research)	4.82 (2.98-7.78)	<.001	2.72 (2.04-3.63)	<.001
High score (clinical)	6.69 (4.31-10.39)	<.001	3.33 (2.48-4.47)	<.001
	Continuous scores multivariate analysis 1 (n = 283)*		Discretized scores multivariate analysis 1 (n = 283)*
High score (research)	4.35 (2.42-7.82)	<.001	2.51 (1.79-3.51)	<.001
Age	1.00 (0.99-1.01)	.18	1.00 (0.99-1.01)	.29
WBC count	1.00 (1.00-1.00)	.001	1.00 (1.00-1.00)	.002
Favorable cytogenetics	0.46 (0.27-0.80)	.006	0.46 (0.26-0.79)	.005
Adverse cytogenetics	1.92 (1.28-2.88)	.001	1.91 (1.29-2.84)	.001
Secondary/t-AML	2.21 (1.49-3.28)	<.001	2.43 (1.64-3.60)	<.001
	Continuous scores multivariate analysis 2 (P < .001) §		Discretized scores multivariate analysis 2 (P < .001) §
High score (research)	1.07 (0.38-2.97)	.88	1.55 (1.01-2.38)	.04
High score (clinical)	4.96 (1.94-12.6)	<.001	2.09 (1.36-3.21)	<.001
Age	1.01 (0.99-1.02)	.06	1.00 (0.99-1.01)	.15
WBC count	1.00 (1.00-1.00)	.01	1.00 (1.00-1.00)	.004
Favorable cytogenetics	0.52 (0.30-0.90)	.02	0.51 (0.29-0.88)	.01
Adverse cytogenetics	1.71 (1.14-2.55)	.008	1.73 (1.16-2.57)	.006
Secondary/tAML	2.13 (1.44-3.15)	<.001	2.26 (1.52-3.36)	<.001

CI, confidence interval; t-AML, therapy-related AML.

^*Number of patients with full clinical annotations are shown.

^†The 95% CI is displayed for each hazard ratio calculated by means of the multivariate Cox regression analysis.

^‡The P-values were calculated by means of the Wald test.

^§Inclusion of LSC17 scores measured by the clinical assay in multivariate model 2 significantly improves predictions of patient outcomes compared with multivariate model 1. P-values were calculated by means of the likelihood ratio test.